Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [18F] FDG PET-CT

Mokhtar,Mohamed; Kondo,Kazuya; Takizawa,Hiromitsu; Ohtani,Tamaki; Otsuka,Hideki; Kubo,Hitoshi; Kajiura,Koichiro; Nakagawa,Yasushi; Kawakami,Yukikiyo; Yoshida,Mitsuteru; Fujino,Haruhiko; Sakiyama,Shoji; Tangoku,Akira

doi:10.3892/or.2014.3056

Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [18F] FDG PET-CT

Authors:
- Mohamed Mokhtar
- Kazuya Kondo
- Hiromitsu Takizawa
- Tamaki Ohtani
- Hideki Otsuka
- Hitoshi Kubo
- Koichiro Kajiura
- Yasushi Nakagawa
- Yukikiyo Kawakami
- Mitsuteru Yoshida
- Haruhiko Fujino
- Shoji Sakiyama
- Akira Tangoku
View Affiliations

Affiliations: Department of Oncological Medical Services, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan, Department of Thoracic, Endocrine and Oncological Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan, Department of Medical Imaging, The University of Tokushima Graduate School, Tokushima, Japan
Published online on: March 5, 2014 https://doi.org/10.3892/or.2014.3056
Pages: 2007-2014

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Positron emission tomography-computed tomography (PET-CT) with [18F] fluorodeoxyglucose (FDG) has recently been applied for evaluating tumor response to anticancer therapy. The aim of the present study was to evaluate the utility of FDG PET-CT in monitoring non-invasively and repeatedly the inhibitory effect of cisplatin (CDDP) on an orthotopic lung cancer model. Validation of in vivo FDG uptake in human lung cancer Ma44-3 cell line in an orthotopic SCID mouse model was carried out. Next, we assessed the use of FDG PET-CT to monitor the response of orthotopic lung cancer to the anticancer effect of CDDP. SCID mice were divided into the CDDP group (7 mg/kg single dose intraperitoneally) and the control group. Tumor volume and maximal standardized uptake value (SUV max) were calculated for all mice. All mice were sacrificed for histopathologic analysis. Validation of FDG PET-CT showed that tumor volume and SUV max were significantly correlated with postmortem tumor length measured in specimens (P=0.023) and (P=0.012), respectively, and there was a significant correlation between SUV max and tumor volume (P=0.048). Response monitoring showed that significant growth inhibition by CDDP in the form of SUV max of the CDDP group was significantly lower than that of the control group on day 8 (P=0.02) and on day 13 (P=0.003). Tumor volume of the CDDP group was significantly lower than that of the control group on day 13 (P=0.03). The present study supports using FDG PET-CT in monitoring tumor progression and therapeutic response of lung cancer in an orthotopic model non‑invasively and repeatedly.

View Figures

View References

1	Fujino H, Kondo K, Ishikura H, et al: Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer. Mol Cancer Ther. 4:1409–1416. 2005. View Article : Google Scholar : PubMed/NCBI
2	Oliver TG, Mercer KL, Sayles LC, et al: Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 24:837–852. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584. 2007. View Article : Google Scholar : PubMed/NCBI
4	Francia G, Cruz-Munoz W, Man S, et al: Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 11:135–141. 2011. View Article : Google Scholar : PubMed/NCBI
5	Bibby MC: Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer. 40:852–857. 2004. View Article : Google Scholar : PubMed/NCBI
6	Miyoshi T, Kondo K, Ishikura H, et al: SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells. Anticancer Res. 20:161–163. 2000.PubMed/NCBI
7	Ishikura H, Kondo K, Miyoshi T, et al: Artificial lymphogenous metastatic model using orthotopic implantation of human lung cancer. Ann Thorac Surg. 69:1691–1695. 2000. View Article : Google Scholar : PubMed/NCBI
8	Ishikura H, Kondo K, Miyoshi T, et al: Suppression of mediastinal metastasis by uracil-tegafur or cis-diamminedichloroplatinum(II) using a lymphogenous metastatic model in a human lung cancer cell line. Clin Cancer Res. 7:4202–4208. 2001.PubMed/NCBI
9	Fujino H, Kondo K, Miyoshi T, et al: Establishment of patient-like SCID mouse model by orthotopically implanting primary cultured cells from surgically-resected lung cancer tissues. Oncol Rep. 10:1709–1715. 2003.PubMed/NCBI
10	Ishikura H, Kondo K, Miyoshi T, et al: Green fluorescent protein expression and visualization of mediastinal lymph node metastasis of human lung cancer cell line using orthotopic implantation. Anticancer Res. 24:719–723. 2004.
11	Kondo K, Fujino H, Miyoshi T, et al: Orthotopically implanted SCID mouse model of human lung cancer suitable for investigating metastatic potential and anticancer drug effects. Oncol Rep. 12:991–999. 2004.PubMed/NCBI
12	Zhang X and Wu J: Establishing of the transplanted animal models for human lung cancer. JNMU. 23:1–5. 2009.
13	Myers R: The biological application of small animal PET imaging. Nucl Med Biol. 28:585–593. 2001. View Article : Google Scholar : PubMed/NCBI
14	Chatziioannou AF: Molecular imaging of small animals with dedicated PET tomographs. Eur J Nucl Med Mol Imaging. 29:98–114. 2002. View Article : Google Scholar : PubMed/NCBI
15	Wahl RL, Jacene H, Kasamon Y, et al: From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 50(Suppl 1): 122S–150S. 2009. View Article : Google Scholar : PubMed/NCBI
16	Pauwels EK, Sturm EJ, Bombardieri E, et al: Positron-emission tomography with [¹⁸F]fluorodeoxyglucose. Part I Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol. 126:549–559. 2000.
17	Kostakoglu L, Hardoff R, Mirtcheva R and Goldsmith SJ: PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 24:1411–1431. 2004. View Article : Google Scholar : PubMed/NCBI
18	Dose Schwarz J, Bader M, Jenicke L, et al: Early prediction of response to chemotherapy in metastatic breast cancer using sequential ¹⁸F-FDG PET. J Nucl Med. 46:1144–1150. 2005.PubMed/NCBI
19	von Falck C, Maecker B, Schirg E, et al: Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [¹⁸F]-FDG-PET(/CT) in initial staging and therapy monitoring. Eur J Radiol. 63:427–435. 2007.PubMed/NCBI
20	Fueger BJ, Czernin J, Hildebrandt I, et al: Impact of animal handling on the results of ¹⁸F-FDG PET studies in mice. J Nucl Med. 47:999–1006. 2006.PubMed/NCBI
21	Jensen MM, Erichsen KD, Björkling F, et al: Early detection of response to experimental chemotherapeutic Top216 with [¹⁸F]FLT and [¹⁸F]FDG PET in human ovary cancer xenografts in mice. PLoS One. 5:e129652010.PubMed/NCBI
22	Paget S: The distribution of secondary growths in cancer of the breast. Lancet. 133:571–573. 1889. View Article : Google Scholar
23	Beyer T, Townsend DW and Blodgett TM: Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med. 46:24–34. 2002.PubMed/NCBI
24	Ell PJ and von Schulthess GK: PET/CT: a new road map. Eur J Nucl Med Mol Imaging. 29:719–720. 2002. View Article : Google Scholar : PubMed/NCBI
25	Tatsumi M, Nakamoto Y, Traughber B, et al: Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer Res. 63:6252–6257. 2003.PubMed/NCBI
26	Kawada K, Murakami K, Sato T, et al: Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. Jpn J Clin Oncol. 37:44–48. 2007. View Article : Google Scholar
27	Kostakoglu L and Goldsmith SJ: ¹⁸F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med. 44:224–239. 2003.
28	Barthel H, Cleij MC, Collingridge DR, et al: 3′-Deoxy-3′-[¹⁸F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 63:3791–3798. 2003.
29	Stimson L and La Thangue NB: Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett. 280:177–183. 2009. View Article : Google Scholar : PubMed/NCBI